Exclusive Patent License AgreementExclusive Patent License Agreement • March 3rd, 2022 • Marinus Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Exclusive Patent License Agreement (“Agreement”), dated and entered into as of March 1, 2022 (the “Effective Date”), is by and between Ovid Therapeutics Inc. a Delaware corporation, with its principal executive offices located at 1460 Broadway, Suite 15044, New York, New York 10036 (“Licensor”) and Marinus Pharmaceuticals, Inc., a Delaware corporation, with its principal executive offices located at 5 Radnor Corporate Center, Suite 500, 100 Matsonford Road, Radnor, Pennsylvania 19087 (“Licensee”). Each of Licensor and Licensee are sometimes referred to herein as a “Party” and collectively as the “Parties.”
